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chatpalliwar@yahoAbstract A stability-indicating liquid chromatographic method has been developed and validated for
the determination of Diltiazem Hydrochloride (DTZ) together with its six related substances (Diltiazem
sulphoxide, Imp-A, Imp-B, Imp-D, Imp-E, and Imp-F) in a laboratory mixture as well as in a novel
tablet formulation developed in-house. Efﬁcient chromatographic separation was achieved on a Hypersil
BDS C18 (150 mm 4.6 mm, 5.0 mm) with mobile phase containing 0.2% Triethylamine (TEA) in
gradient combination with acetonitrile (ACN) at a ﬂow rate of 1.0 mL/min and the eluent was monitored
at 240 nm. In the developed method, the resolution of DTZ from any pair of impurities was found to be
greater than 2.0. The test solution and related substances were found to be stable in the diluent for 24 h.
The developed method resolved the drug from its known impurities, stated above, and also from
additional impurities generated when the formulation was subjected to forced degradation; the mass
balance was found close to 99.9%.
Regression analyses indicate correlation coefﬁcient value greater than 0.997 for DTZ and its six known
impurities. The LOD for DTZ and the known impurities was at a level below 0.02%. The method
has shown good, consistent recoveries for DTZ (99.8–101.2%) and also for its six known impurities
(97.2–101.3%). The method was found to be accurate, precise, linear, speciﬁc, sensitive, rugged, robust,
and stability-indicating.
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1. Introduction
Diltiazem Hydrochloride (DTZ), 3-(acetyloxy)-5-[2-(dimethyla-
mino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-1, 5-benzothiazepin
-4(5H)-one monohydrochloride (Fig. 1) [1] – a calcium channel
blocker which inhibits inﬂux of calcium (Ca2þ) ions – is used for
treatment of several cardiovascular disorders [2], viz. essential
hypertension [3] and supraventricular tachyarythmias [4].
Regulatory requirements for the identiﬁcation, qualiﬁcation,
and control of impurities in drug substances and their formulated
products are now being explicitly deﬁned, particularly through the
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1,5-benzothiazepin-3-yl acetate; Diltiazem impurity-B  
C. R1 = CO-CH 3 , R2 = CH 2 -CH 2 -N(CH 3 ) 2 , R3 = OH: 
(2S,3S)-5-[2-(dimethylamino)ethyl]-2-(4-
hydroxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate; Diltiazem 
impurity-C  
D.  R1  =  CO-CH 3 ,  R2  =  CH 2 -CH 2 -NH-CH 3 ,  R3  =  OCH 3 :  
(2S,3S)-2-(4-methoxyphenyl)-5-[2- 
(methylamino)ethyl]-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate; Diltiazem
impurity-D 
E.  R1  =  R2  =  H,  R3  =  OCH 3 :  
(2S,3S)-3-hydroxy-2-(4-methoxyphenyl)-2,3-dihydro-1,5- 
benzothiazepin-4(5H)-one; Diltiazem impurity-E  
F.  R1  =  H,  R2  =  CH 2 -CH 2 -N(CH 3 ) 2 ,  R3  =  OCH 3 :  
(2S,3S)-5-[2-(dimethylamino)ethyl]-3- 
hydroxy-2-(4-methoxyphenyl)-2,3-dihydro-1,5-benzothiazepin-4(5H)-one; Diltiazem 
impurity-F 
(2S,3S)-5-[2-(dimethylamino)ethyl]-3-hydroxy-2-(4-methoxyphenyl)-2,3-dihydro-1,5- 
benzothiazepin-4(5H)-one 1-Oxide; Diltiazem sulphoxide 
Figure 1 Chemical structures of Diltiazem Hydrochloride and its related substances.
Stability-indicating liquid chromatographic method for diltiazem hydrochloride 227International Conference on Harmonization (ICH). It is also
recommended by ICH that all routine impurities at or above 0.1%
level, should be identiﬁed through appropriate analytical methods
[5–7]. DTZ is cited in the British Pharmacopoeia to have
contamination by compounds A, B, C, D, E, and F (Fig. 1) [8].
Therefore, it was thought worth determining the impurities of
DTZ to ensure the quality, efﬁcacy and safety of the ﬁnalpharmaceutical formulation. Of the six ofﬁcial impurities, a
method for analyzing DTZ in the presence of ﬁve impurities,
namely A, B, D, E, and F, was required to be developed.
Diltiazem sulphoxide [9], a reported impurity, is likely to be
present in formulations of DTZ.
Numerous analytical methods for the determination of DTZ in
bulk drug as well as in formulations have been reported in
V.A. Chatpalliwar et al.228literature viz. spectrophotometry [10,11], gas chromatography [12],
HPTLC [13], HPLC [14–18]. Recently, HPLC–MS and CE
methods have been reported to characterize the DTZ metabolites
[19–22]. A RP-HPLC method using monolithic silica support for
separation of DTZ and its impurities has been published [23]. Two
validated stability indicating HPLC methods have also been
reported for DTZ in bulk drug [24] and in tablets [25]. These
stability indicating analytical methods are validated for assay of
DTZ, and not for analyzing the drug in the presence of its known
impurities.
An HPLC method for assay of Diltiazem Hydrochloride
and its related substances (RS) in bulk drug and ﬁnished
tablets is reported [26] without any comment on the stability
indicating potential of the method.
From preceding details of relevant literature it was apparent
that a validated method is required to be developed which would
be capable for simultaneous determination of DTZ in the presence
of its reported impurities, and also serve as stability-indicating.
Thus, the aim of current study was to develop and validate an LC
method for the determination of DTZ and its known impurities
(Diltiazem sulphoxide, Imp-A, Imp-B, Imp-D, Imp-E, and Imp-F)
along with degradation products, in a novel tablet dosage form, in
accordance with the ICH guidance document [27].2. Experimental
2.1. Reagents and chemicals
Qualiﬁed standards of DTZ and Diltiazem sulphoxide were gifted
by Torrent Research Center (Ahmadabad, India). Following
authenticated impurity standards were obtained from Stride
Arcolab Limited (Bangalore, India): Imp-A, Imp-B, Imp-D,
Imp-E, and Imp-F. Novel sustained release tablets of DTZ and
a placebo were formulated in Department of Pharmaceutics,
S.S.D.J. Coll. Pharm., Neminagar, Chandwad, India. The exci-
pients used to formulate the tablets were aerosol 200 and eudragit
and magnesium stearate which were procured from local supplier.
Analytical/HPLC grade chemicals and solvents used were
obtained from Ranbaxy Fine Chemicals Limited (Delhi, India).2.2. Chromatography apparatus and conditions
The chromatograph consisted of an HP-Agilant 1100 HPLC
system with G1311A quaternary pump, G1315A diode array
detector and variable wavelength detector, a G1313A auto-
sampler, and a G1322A vacuum degasser. The data were
evaluated by HP Chemstation Software.
DTZ, pKa 7.7 [28], was freely soluble in selected analytical
solvents like water, acetonitrile (ACN) and methanol
(MeOH). The chromatographic conditions were optimized
by different means (using different columns, different buffers
and different organic phases). Early chromatographic work
was performed with different brands of C8 and C18 columns
as stationary phase and various combinations of buffered
(pH 4.5–5.0) organic phases (ACN and/or methanol). The
ﬂow rate of mobile phase was varied within 1.0–1.5 mL/min.
Wavelength for monitoring the eluent was selected by scan-
ning standard solution of drug within 200–400 nm using
double beam UV–visible spectrophotometer (Shimadzu 1800,
Japan).All noted measurements were performed with an injection
volume of 10 mL and UV detection at 240 nm of samples
dissolved in a diluent; Mobile phase-A [0.2% triethylamine
(TEA) pH adjusted to 4.5 with o-phosphoric acid (o-PA)]:
Mobile phase-B [ACN] in 3:2 (v/v).
2.3. Preparation of solutions
2.3.1. Preparation of resolution solution
On lines with ofﬁcial procedures [8], impurity stock solutions
of Diltiazem impurity-A and Diltiazem impurity-D (50 mg/mL,
each) were individually prepared by dissolving their appropriate
amounts in the diluent. DTZ (25 mg) was dissolved in 60 mL of
diluent in a 100 mL volumetric ﬂask. To this solution, 2.5 mL of
each of above impurity solutions was added and sonicated in
cool condition (10 1C72) for 10 min. The volume of thus
obtained clear solution was made up to 100 mL with the diluent
to give the resolution solution containing 250 mg/mL DTZ, and
1.25 mg/mL each of Imp-A and Imp-D.
Diluted standard of DTZ (1.25 mg/mL) was prepared by
dissolving appropriate amount of the drug in the diluent.
Similar method was employed to prepare diluted solutions of
Diltiazem sulphoxide, Imp-B, Imp-E and Imp-F to contain
1.25 mg/mL.
2.3.2. Preparation of laboratory mixture solutions
Appropriate amounts of active pharmaceutical ingredient
(DTZ), Diltiazem suphoxide, Imp-A, Imp-B, Imp-D, Imp-E,
and Imp-F, and amount of excipients equivalent to average
weight of tablet was transferred to a 200 mL volumetric ﬂask,
100 mL of diluent was added and sonicated for 15 min with
intermittent shaking and diluted to volume with the diluent to
contain 250 mg/mL DTZ, and 1.25 mg/mL each of known
impurities. This solution was ﬁltered through a 0.45 mm Nylon
66-membrane ﬁlter and used for the analysis.
2.3.3. Preparation of sample solution
An amount of powdered tablet (In-house DTZ SR, 60 mg)
equivalent to 50 mg of the active pharmaceutical ingredient
(DTZ) was transferred to a 200 mL volumetric ﬂask. Diluent
(100 mL) was added to it and sonicated for 15 min with
intermittent shaking and diluted to volume with the diluent. This
solution was ﬁltered through a 0.45 mmNylon 66-membrane ﬁlter
and used for the analysis. Similar method was employed to
prepare placebo solution.
2.4. System suitability
System suitability parameters were evaluated to verify that the
analytical system is working properly and can give accurate
and precise results. Parameters such as peak asymmetry
factor, tailing factor, resolution between Imp-A and Imp-D,
resolution between Imp-D and DTZ, and % RSD of theore-
tical area obtained from two diluted standard solutions of
DTZ (in triplicate), were evaluated.
2.5. Filter-compatibility studies
Laboratory mixture solution was subjected to ﬁlter-compat-
ibility studies. The solution was ﬁltered using Whatman
ﬁlter paper no. 42 and 0.45 mm Nylon 66-membrane ﬁlter.
Table 1 Linearity parameters of the calibration curves for DTZ and its RS.
Compound Linearity range
(lg/mL)
R2 Slope Intercept Standard
error
t-Stat P-value FR
DTZ 0.35–1.50 0.999 34.62 0.80 0.39 2.05 0.06
Diltiazem sulphoxide 0.20–1.50 0.998 32.76 0.33 0.32 1.01 0.33 0.95
Diltiazem Impurity-F 0.12–7.50 0.998 40.78 2.73 2.31 1.35 0.20 1.17
Diltiazem Impurity-A 0.30–1.50 0.997 25.19 0.62 0.32 1.90 0.08 0.73
Diltiazem Impurity-E 0.30–1.50 0.998 60.15 1.00 0.65 1.53 0.15 1.74
Diltiazem Impurity-B 0.20–1.50 0.999 53.87 0.67 0.49 1.37 0.20 1.56
Diltiazem Impurity-D 0.27–1.50 0.998 33.44 0.65 0.38 1.74 0.10 0.97
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tered). Chromatography was performed on these three solu-
tions, in triplicate, and difference between concentrations of
each component in ﬁltered and unﬁltered sample solutions was
calculated.2.6. Analytical method validation
2.6.1. Speciﬁcity
Speciﬁcity is the ability of the method to measure the analyte
response in the presence of its potential impurities and
degradation products. These studies were performed in two
parts, Speciﬁcity part-A and Speciﬁcity part-B.
In Speciﬁcity part-A, separation and resolution were
observed between DTZ standard solution, placebo solution,
and its six impurities, namely Diltiazem sulphoxide, Imp-A,
Imp-B, Imp-D, Imp-E, and Imp-F (known impurities). In
Speciﬁcity part-B, sample was subjected to various stress
conditions [29], viz. different levels of acidic hydrolysis, alka-
line hydrolysis, neutral hydrolysis, and oxidation conditions at
a concentration of 1 mg/mL. Samples were also subjected to
thermal and photo-degradation in dry state. Chromatography
was performed for stressed sample solutions and calculations
were done using area normalization method. The mass
balance studies were done for each type of stress study.2.6.2. Linearity
Linearity test for the method was performed according to the
guidelines laid by ICH. Appropriate aliquots of DTZ stock
solution were spiked with appropriate volumes of stock
solutions of known impurities (related substances) and diluted
with the diluent to get solutions containing required concen-
trations. Linearity of DTZ and its RS was determined over a
range of obtained limit of quantiﬁcation (mentioned in
Table 1) to 300% of speciﬁcation limit (range was inclusive
of concentrations at LOQ, 50, 80, 100, 120, 150, 200
and 300%).
Calibration curve was drawn by plotting the peak areas of
DTZ and RS versus its corresponding concentration. The
process was repeated for three consecutive days (twice each
day) in the same concentration range. Values of coefﬁcient of
regression, slope and Y-intercept of the calibration curve were
calculated. The relative response factors (FR) of all RS were
calculated and concentrations were adjusted accordingly.2.6.3. Precision
Six solutions containing DTZ (250 mg/mL) were spiked with
RS solutions 1.25 mg/mL (a 0.15% of DTZ concentration).
Chromatography was performed and value of % RSD was
calculated considering peak area for DTZ and each RS.
Similarly, intermediate precision of the method was also
evaluated by another analyst, on a different day in the same
laboratory.
2.6.4. Limit of detection (LOD) and limit of quantiﬁcation
(LOQ)
The LOD and LOQ for DTZ and all RS were estimated by
signal-to-noise ratio, 3:1 and 10:1, respectively, injecting a
series of six diluted solutions with known concentrations.
2.6.5. Accuracy
Recovery studies were performed in triplicate at concentration
levels of 50, 100, 200 and 300% of DTZ (250 mg/mL) to
evaluate the accuracy of the proposed method. Solutions for
the purpose were prepared by standard addition of DTZ stock
solution to laboratory mixture solution.
2.6.6. Stability of laboratory mixture solution
The stability of DTZ stock solution (250 mg/mL) and labora-
tory mixture solution was evaluated at regular intervals for
24 h. The difference in areas of respective peaks in the
obtained chromatograms was calculated.
2.6.7. Robustness
The method was performed with little variations like changing
the pH (70.2 unit) of mobile phase, changing the mobile
phase ﬂow rate (70.2 mL/min), and increasing the tempera-
ture from normal (75 1C). Chromatograms of six replicas of
laboratory mixture solution were obtained and effect of each
deliberate change was evaluated by applying system suitability
parameters and calculating value of % RSD for each delib-
erate change.3. Results and discussion
3.1. Development of the stability-indicating chromatographic
method
Ofﬁcial HPLC method [8] to analyze DTZ and its RS (Imp-A)
was not found to be stability-indicating. Following these
methods to analyze stability-indicating samples of DTZ tablets
V.A. Chatpalliwar et al.230– produced by acid, alkali, hydrogen peroxide, heat and light
treatment and spiked with laboratory mixture solution – did
not yield satisfactory results. The methods were not able to
produce sufﬁcient resolution between degradation products
with the RS. The chromatogram of sample containing degra-
dation products generated by oxidative stress showed elution
of Diltiazem sulphoxide (relative retention time 0.35) which
did not meet the acceptance criteria for peak purity, assessed
by a PDA detector. Additionally, the method applied to
stability-indicating samples of alkaline degradation yielded a
chromatogram displaying co-elution of degradation products
at RRT 0.68 with Impurity-F.
Therefore, the reported method [8] was modiﬁed to get
better peak shape and resolution amongst peaks of all
degradation products, RS and DTZ.
Another ofﬁcial method [1] required longer saturation time
of HPLC-system, probably due to the use of an ion-pair
reagent in the mobile phase. Although, some other reported
methods [18,25] were also considered, in that the degradation
products were either not well resolved or co-eluted with DTZ
related impurities.
The method which was thought to be developed was
envisaged to be capable of eluting wide range of compounds
of different polarities, with excellent efﬁciency and sufﬁcient
band spacing. During development of chromatography, elu-
tion was performed using C18 columns. Mobile phase consist-
ing of ACN, MeOH and 50 mM potassium phosphate buffer
(25:25:50) with pH 5.5 was used preliminary in isocratic
elution. The chromatogram showed co-elution of Imp-A and
Imp-D with DTZ. Further, increasing the proportion of ACN
in the mobile phase resulted in rapid elution of Diltiazem
sulphoxide. Replacement of the potassium phosphate compo-
nent with o-PA yielded a mobile phase ACN: MeOH: o-PA
(30:15:55) with pH 5.0 and ﬂow rate 1.0 mL/min gave
optimum resolution in separate peaks of DTZ and RS,
although tailing was observed in few peaks. This tailing was
gradually removed to some extent by addition of aqueous
TEA (0.2%, v/v). However, proper resolution amongst the
degradation products in stability samples was not obtained.
Therefore, a gradient mode of elution was tried for greater
chance of success in the context. The gradient mobile phase
consisted of two major components: Mobile Phase A containing
aqueous TEA (0.2%, v/v) whose pH was adjusted to 5.0 with
o-PA, and Mobile Phase B was ACN. The ﬁnally developed
gradient method was consist of % change in mobile phase B with
respect to time (0.01-34.99 min: 22% B; 35.00-44.99 min: 33%
B; 45.00-60.00 min: 38% B). The mobile phase was mixed and
eluted at 1.0 mL/min by the system and column temperature was
maintained at 25 1C.Figure 2 ChromatogramOptimum separation conditions were obtained with a BDS
(Thermo Hypersil BDS, 150 mm 4.6 mm i.d. with 5.0 mm
particles) column, injection volume 10 mL, column oven
temperature maintained at 25 1C, monitoring the elution by
a UV detector at 240 nm.
3.2. System suitability
Chromatographic separation was performed with C18 column
(Thermo Hypersil BDS, 150 mm 4.6 mm i.d., 5.0 mm parti-
cles) with the above mentioned gradient mobile phase and a
representative chromatogram is shown in Fig. 2, which display
a tailing factor less than 1.5 for all the peaks, a resolution of
4.5 and 2.2 for Imp-A and Imp-D with respect to DTZ,
respectively. The ratio of the peak areas of diluted DTZ
standard solution and % RSD of six injections were 0.995 and
1.6, respectively.
Tailing factor, a parameter that ICH guidelines consider as
a factor to be controlled, was within the established limits. The
resolution factor between two consecutive peaks approxi-
mately represents twice the minimum request to be considered.
3.3. Filter compatibility studies
The results of ﬁlter compatibility studies performed and
compared for unﬁltered and ﬁltered methods are tabulated
in Table 2, and indicate that either 0.45 mm ﬁlter or Whatman
ﬁlter can be used for regular analysis.
3.4. Speciﬁcity
The HPLC chromatograms recorded separately for DTZ
alone and with its RS, blank and placebo preparations
displayed a single, non-overlapped, peak for DTZ, as shown
in Figs. 3, 4, 5 and 6, respectively. The resolution factor
obtained between peak for DTZ and other peaks was more
than 2.1 and the tailing factor of peak for DTZ and the RS
was always in the range of 1.03–1.50. Thus, the HPLC method
presented in this study is selective for DTZ and also for the
other six related compounds, which might co-exist as impu-
rities. HPLC results of speciﬁcity part-B (forced degradation
studies) of DTZ, suggested the following degradation beha-
vior; results are tabulated in Table 3.
3.4.1. Degradation in acidic conditions
DTZ was observed to be degraded to about 76% in acidic
conditions, when treated with 0.1 M HCl for 1 h at 80 1C.
Impurity-F was obtained as single degradation productof resolution solution.
Table 2 Peak area difference of ﬁltered sample solutions with unﬁltered sample.
Compound Difference with unﬁltered sample (%)
Set-1 Set-2
0.45 mm ﬁlter Whatman ﬁlter 0.45 mm ﬁlter Whatman ﬁlter
Diltiazem sulphoxide 1.5 1.7 0.4 3.7
Dilitazem Impurity-F 1.7 2.7 0.5 0.1
Dilitazem Impurity-A 0.8 2.6 0.1 0.2
Dilitazem Impurity-D 1.5 0.4 1.4 3.7
Dilitazem Impurity-E 1.8 4.2 1.0 0.2
Dilitazem Impurity-B 1.6 6.6 0.9 1.0
Total impurity 1.0 0.7 0.8 0.0
Figure 3 Chromatogram of DTZ standard solution.
Figure 4 Chromatogram of DTZ and its RS.
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found to be stable (E98.0% remaining) at reduced stress
conditions (0.01 M HCl for 1 h at 80 1C) with Imp-F as the
only degradation product (Fig. 7B).
3.4.2. Degradation in basic conditions
DTZ was found to be degraded to 72.7% under basic
conditions, when treated with 0.1 M NaOH for 1 h at 80 1C.
The chromatogram obtained on analyzing the stability sample
(Fig. 8A) displayed more than seven peaks for degradation
products; Impurity-F being obtained as major degradationproduct (22.06%), eluted at 0.58 RRT. DTZ was found stable
(E98.5% remaining) at reduced stress conditions (0.01 M
NaOH for 1 h at 80 1C) with Imp-F as the only degradation
product as shown in Fig. 8B.
Results of degradation studies suggest that long term
storage of the drug leads to degradation, with fall in the
content of DTZ and corresponding rise in Imp-F.
3.4.3. Degradation under oxidative conditions
The drug was reduced to 43% on peroxide degradation (3%
H2O2 at 80 1C for 1 h) with Diltiazem sulfoxide as a major
Figure 5 Chromatogram of diluent (blank) used in the study.
Figure 6 Chromatogram of placebo preparation used in tablet formulation.
Table 3 Speciﬁcity part-B (stress) studies representing degradation in various parameters.
Degradation
stages
Condition DTZ (remaining
% by area
normalization)
SKMI (% by area
normalization/
RRT/name)
MUDP (by
area %/RRT)
No. of degradation
products
Mass
balance
(%)
As such 100.00 0 – – –
Acid degradation a 76.19 23.52/0.58/Imp-F – 1 99.71
b 98.35 1.64/0.58/Imp-F – 1 99.99
Base degradation a 72.71 22.06/0.58/Imp-F 2.20/0.39 7 99.90
b 98.43 1.57/0.58/Imp-F No peak 1 99.90
Peroxide degradation a 43.31 29.86/0.28/
Diltiazem
sulphoxide
12.53/0.11 14 99.91
b 98.02 0.58/0.29/Diltiazem
sulphoxide
– 2 99.90
Neutral degradation 99.72 0.28/0.58/Imp-F – 1 100.00
Thermal stress 100.00 – – – 100.00
UV light exposed 100.00 – – – 100.00
‘As such’¼no stress condition applied, RRT¼relative retention time with respect to DTZ peak, a¼high stress, b¼moderate stress (as
explained in text), SKMI¼single known maximum impurity, MUDP¼major unknown degradation product, ‘–’¼no peak observed.
V.A. Chatpalliwar et al.232degradation product (29.86%) eluting at 0.28 RRT. The
chromatogram obtained on analyzing the stability sample
(Fig. 9A) displayed more than 14 degradation products, of
which, a major unknown degradation product (12.53%) wasobserved at 0.11 RRT. DTZ was relatively stable (98.02%
remaining) at milder oxidative degradation conditions (3%
H2O2 at 80 1C for 10 min) with Imp-D and Imp-F as the
degradation products (Fig. 9B).
Figure 7 Chromatograms of acid stressed samples treated with 0.1 M HCl at 80 1C for 1 h (A) and 0.01 M HCl at 80 1C for 1 h (B).
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DTZ was found to be practically stable under the exposed
conditions with an overall illumination of 1.2 million lx h with
near-UV energyZ200 Wh/m2; the chromatogram is given in
Fig. 10. This suggests that the drug was stable under photo-
lytic conditions exposed for the period of study.
3.4.5. Thermal degradation
DTZ was found to be practically stable with dry heat as no
degradation was observed when exposed to thermal heat at
80 1C for 8 h; the chromatogram is given in Fig. 11.
3.4.6. Degradation under neutral conditions
DTZ was found to have a negligible degradation of about
0.25% under neutral conditions (reﬂuxed in water for 2 h at
80 1C) as only two degradation products were formed under
the conditions studied; the chromatogram is given in Fig. 12.
3.5. Linearity
Calibration curves for DTZ and its RS, examined in pure
solutions as well as in the laboratory mixture solutions, were
found to be linear; correlation coefﬁcientsZ0.997 in all the
cases. Table 1 enlists the linearity parameters of the calibration
curves for DTZ and its RS in laboratory mixture. UV-relativeresponse factors (FR) were calculated for each impurity using
the following equation: FR¼Simpurity/SDTZ.
Where, Simpurity is slope of regression line for a given impurity
and SDTZ is the slope of the regression line for DTZ. Concentra-
tions of DTZ and impurity were corrected. Statistical treatment
of the linearity data of DTZ shows a linear response between
lower levels to highest level. In addition, the analysis of residuals
shows values randomly scattered around zero, which ﬁts well
within the linear model. The origin of linearity curve was within
the lower and the upper limit of 95% that gives high degree of
conﬁdence to the value obtained for intercept.
3.6. LOD and LOQ
LOD and LOQ, as a measure of method sensitivity, were
provided for degradation products and impurity calculated by
means of signal-to-noise ratio. The LOD and LOQ for DTZ
and its RS are tabulated in Table 4. From the results, it can be
concluded that the proposed method can quantify small
quantity of impurities in DTZ samples.
3.7. Precision and repeatability
The results obtained for repeatability studies and for inter-
mediate precision are presented in Table 5. Values of % RSD
Figure 8 Chromatograms of alkali stressed samples treated with 0.1 M NaOH at 80 1C for 1 h (A) and 0.01 M NaOH at 80 1C for
1 h (B).
Figure 9 Chromatograms of peroxide stressed samples treated with 3% H2O2 reﬂuxed at 80 1C for 1 h (A) and 3% H2O2 reﬂuxed at
80 1C for 10 min (B).
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0.8, respectively. Method precision has a % RSD below 1.9
for repeatability and 1.4 for intermediate precision, which
comply with the acceptance criteria.Figure 10 Chromatogram of photo stressed sample.
Figure 11 Chromatogram of thermal stressed sample.
Figure 12 Chromatogram o
Table 4 LOD and LOQ results for DTZ and its RS.
Compound LOD
Concentration (lg/mL) % RSD of injectio
DTZ 0.12 11.40
Diltiazem sulphoxide 0.07 9.80
Diltiazem Impurity-F 0.05 19.30
Diltiazem Impurity-A 0.10 14.20
Diltiazem Impurity-E 0.10 12.60
Diltiazem Impurity-B 0.07 10.90
Diltiazem Impurity-D 0.10 16.803.8. Accuracy
The results are expressed as percent recoveries of the particular
components in the samples. Table 6 shows that the overall
percent recoveries of DTZ and its six RS at 50, 100, 200 and
300% of the test concentration. The method has shown good,
consistent recoveries for DTZ (99.8–101.2%). However, the
related compounds showed overall percent recoveries ranging
from 97.9 to 102.8 with % RSD ranging from 1.2 to 3.1.3.9. Stability in analytical solution
The % area change in peaks of DTZ and all impurities was
less than 2.0% and 5.0%, respectively. From the data
tabulated in Table 7, it was concluded that standard and
sample solutions may be used up to 24 after preparation.3.10. Robustness
Method robustness checked after deliberate alterations of
mobile phase composition, ﬂow, pH and temperature shows
that the changes of the operational parameters do not lead to
essential changes of the performance of the chromatographic
system; results are displayed in Table 8. Tailing factor for
DTZ and its RS always ranged from 1 to 1.5 and the
components were well separated. The percent recoveries of
DTZ and RS were good and did not show a signiﬁcant change
when the critical parameters were modiﬁed. Considering the
results of modiﬁcations in the system suitability parameters
and the speciﬁcity of the method, it would be concluded that
the method conditions are robust.f neutral stressed sample.
LOQ
n (n¼6) Concentration (lg/mL) % RSD of injection (n¼6)
0.35 6.90
0.20 4.30
0.12 4.00
0.30 3.30
0.30 6.10
0.20 5.30
0.27 7.70
Table 5 Intra-day and intermediate precision of DTZ and its RS (% RSD of n¼6 injections of test concentration).
Compound Intra-day precision Intermediate precision
System precision Method precision Different day
DTZ 0.3 1.0 0.9
Diltiazem sulphoxide 0.8 1.7 0.7
Impurity-F 0.9 1.2 1.0
Impurity-A 0.4 1.9 1.7
Impurity-D 0.7 1.8 1.9
Impurity-E 0.8 1.5 0.8
Impurity-B 1.0 1.8 1.1
Total impurity 0.8 1.9 1.4
Table 6 Accuracy results of DTZ and its RS in the term of RSD (%) of mean recovery (%).
Added
(%)
DTZ Diltiazem
sulphoxide
Impurity-F Impurity-A Impurity-D Impurity-E Impurity-B
MR
(%)
RSD
(%)
MR
(%)
RSD
(%)
MR
(%)
RSD
(%)
MR
(%)
RSD
(%)
MR
(%)
RSD
(%)
MR
(%)
RSD
(%)
MR
(%)
RSD
(%)
50 99.8 1.9 98.2 1.5 99.6 2.2 97.5 3.1 100.8 1.2 102.1 2.8 100.9 2.1
100 101.2 2.0 99.5 2.1 102.8 2.4 100.2 1.9 99.6 1.8 100.8 1.2 97.9 1.6
200 100.9 1.4 100.5 2.4 98.4 1.5 100.9 2.1 100.2 1.4 98.5 1.9 102.5 2.2
300 101.7 1.9 98.9 1.6 99.1 2.1 99.0 1.3 101.6 1.8 99.7 2.0 100.1 1.1
MR: mean recovery, n¼3.
Table 7 Stability of DTZ and its RS in analytical solution (one day study).
Compound Initial area 12 h 18 h 24 h
Area Difference (%) Area Difference (%) Area Difference (%)
DTZ 36.15969 37.01846 2.4 37.59764 4.0 36.86213 1.9
Diltiazem sulphoxide 13.71313 14.14156 3.1 13.67648 0.3 13.71130 0.0
Impurity-F 89.97086 89.69975 0.3 91.34973 1.5 92.72081 3.1
Impurity-A 9.40208 9.34010 0.7 9.03424 3.9 9.74495 3.6
Impurity-E 24.32384 24.34320 0.1 24.27540 0.2 24.36614 0.2
Impurity-B 21.66869 21.68923 0.1 20.83593 3.8 21.72877 0.3
Impurity-D 13.51299 13.41356 0.7 13.20469 2.3 14.12792 4.6
Total impurity 172.59161 172.62739 0.0 172.37648 0.1 176.39990 2.2
Table 8 Effect of various deliberated changes on the system suitability parameters.
System suitability
conditions
Resolution between
Diltiazem Imp-A and Imp-D
Resolution between
Imp-D and DTZ
Ratio between the
duplicate injection
% RSD for DTZ standard
replicate injections
Initial 1.0 mL 3.5 2.2 0.97 1.06
Change in ﬂow 1.2 mL 3.1 2.3 0.99 1.54
0.8 mL 2.7 2.4 1.01 1.06
Change in column
temperature
þ5 1C 2.7 2.4 1.00 0.62
5 1C 3.0 2.2 1.02 1.78
Change in pH units 0.2 2.5 2.8 0.99 1.63
þ0.2 1.5 4.8 1.04 1.61
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The proposed HPLC method for estimation of related sub-
stances for Diltiazem Hydrochloride, is analyzed in bulk drug
and DTZ SR tablets as per ICH guidelines. The method is
found to be speciﬁc for the estimation of known, unknown
impurities and degradation products. The method is also
stability indicating as evident from results obtained when
method applied to stability samples. The assay utilized a
previously unreported set of conditions, including a gradient
ramp and simple mobile phases, to effect the separation
without using an ion-pair reagent. LOD and LOQ, established
by this method, are lesser than earlier reported methods. The
method is found to be linear in the speciﬁed range, precise and
robust. Accuracy of the method is also established for the
formulation. Hence, the proposed method stands validated
and may be used for routine and stability sample analysis.
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